{"id":221037,"date":"2025-08-27T01:17:23","date_gmt":"2025-08-27T06:17:23","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2025\/08\/first-ever-treatment-for-rare-eye-disease-wins-fda-approval-after-landmark-trials"},"modified":"2025-08-27T01:17:23","modified_gmt":"2025-08-27T06:17:23","slug":"first-ever-treatment-for-rare-eye-disease-wins-fda-approval-after-landmark-trials","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2025\/08\/first-ever-treatment-for-rare-eye-disease-wins-fda-approval-after-landmark-trials","title":{"rendered":"First-Ever Treatment for Rare Eye Disease Wins FDA Approval After Landmark Trials"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/first-ever-treatment-for-rare-eye-disease-wins-fda-approval-after-landmark-trials.jpg\"><\/a><\/p>\n<p>Phase 3 clinical trial results from Scripps Research and its collaborators supported FDA approval of ENCELTO, the first cell-based treatment for the neurodegenerative retinal disease known as MacTel. For individuals with macular telangiectasia type 2 (MacTel), a rare retinal disease that steadily<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Phase 3 clinical trial results from Scripps Research and its collaborators supported FDA approval of ENCELTO, the first cell-based treatment for the neurodegenerative retinal disease known as MacTel. For individuals with macular telangiectasia type 2 (MacTel), a rare retinal disease that steadily<\/p>\n","protected":false},"author":427,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,47],"tags":[],"class_list":["post-221037","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-neuroscience"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/221037","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/427"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=221037"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/221037\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=221037"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=221037"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=221037"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}